Atlas Trials

Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis

Clinical trial NCT05178810 · COMPLETED

Trial details

NCT number
NCT05178810
Sponsor
Ferrer Internacional S.A.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Amyotrophic Lateral Sclerosis
Start date
2021-10-18
Primary completion
2023-10-26
Enrollment
313

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.